Collegium Pharmaceutical, Inc. (COLL) P/E Ratio History
Fairly ValuedTrading at 24.8x, near 5Y avg of 27.2x · 65th percentile · In line with own history · Data 2020–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, Collegium Pharmaceutical, Inc. (COLL) trades at a price-to-earnings ratio of 24.8x, with a stock price of $24.21 and trailing twelve-month earnings per share of $0.98.
The current P/E is roughly in line with its 5-year average of 27.2x. Over the past five years, COLL's P/E has ranged from a low of 7.5x to a high of 149.0x, placing the current valuation at the 65th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, COLL is roughly in line with its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
The PEG ratio of 1.39 (P/E divided by -7% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, COLL trades roughly in line with the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our COLL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
COLL Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
COLL P/E vs Peers
Branded Specialty Pharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 11.1 | - | +8% | |
| $3B | 7.1Lowest | - | +10833%Best | |
| $1B | 39.4 | - | +107% | |
| $124B | 26.3 | - | +49% | |
| $64B | 34.8 | 1.23 | +12% | |
| $107B | 9.8 | - | -62% | |
| $1B | 7.1 | 0.69Best | +817% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
COLL Historical P/E Data (2020–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | Sep 30 2026 | $21.82 | $1.00 | 21.8x | -20% |
| FY2026 Q2 | - | $36.20 | $1.24 | 29.2x | +7% |
| FY2026 Q1 | - | $33.07 | $2.04 | 16.2x | -40% |
| FY2025 Q4 | Dec 31 2025 | $46.30 | $1.71 | 27.0x | -1% |
| FY2025 Q3 | - | $34.99 | $1.60 | 21.8x | -20% |
| FY2025 Q2 | Jun 30 2025 | $29.57 | $1.03 | 28.6x | +5% |
| FY2025 Q1 | Mar 31 2025 | $29.85 | $1.21 | 24.6x | -10% |
| FY2024 Q4 | - | $28.65 | $1.85 | 15.5x | -43% |
| FY2024 Q3 | Sep 30 2024 | $38.64 | $2.32 | 16.7x | -39% |
| FY2024 Q2 | Jun 30 2024 | $32.20 | $2.58 | 12.5x | -54% |
| FY2024 Q1 | Mar 31 2024 | $38.82 | $2.40 | 16.2x | -41% |
| FY2023 Q4 | Dec 31 2023 | $30.78 | $1.18 | 26.1x | -4% |
| FY2023 Q3 | Sep 30 2023 | $22.35 | $0.15 | 149.0x | +448% |
| FY2022 Q1 | - | $20.36 | $0.89 | 22.9x | -16% |
| FY2021 Q4 | Dec 31 2021 | $18.68 | $1.69 | 11.1x | -59% |
| FY2021 Q3 | - | $19.75 | $2.62 | 7.5x | -72% |
| FY2021 Q2 | Jun 30 2021 | $23.64 | $2.72 | 8.7x | -68% |
| FY2021 Q1 | Mar 31 2021 | $23.70 | $1.16 | 20.4x | -25% |
| FY2020 Q4 | - | $20.03 | $0.76 | 26.4x | -3% |
| FY2020 Q3 | Sep 30 2020 | $20.82 | $0.49 | 42.1x | +55% |
Average P/E for displayed period: 27.2x
COLL Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
COLL — Frequently Asked Questions
Quick answers to the most common questions about buying COLL stock.
What is COLL's P/E ratio?
Collegium Pharmaceutical, Inc. (COLL) trailing twelve-month P/E ratio is 24.8x, based on TTM diluted EPS of $0.98. The 5-year average P/E is 27.2x and the historical range spans 7.5x to 149.0x.
Is COLL stock overvalued or undervalued?
COLL trades at 24.8x P/E, near its 5-year average of 27.2x. The 65th percentile ranking within the 7.5x–149.0x historical range places valuation within normal bounds.
Is COLL stock expensive?
COLL is fairly valued relative to its own history. The current P/E of 24.8x is near the 5-year average of 27.2x (65th percentile of historical range).
What is COLL's historical P/E range?
Over the past 5 years, COLL's P/E ratio has ranged from 7.5x to 149.0x, with a median of 21.8x and an average of 27.2x. The current P/E of 24.8x places the stock at the 65th percentile of this range. Full historical data spans 2020–2026.
How does COLL's P/E compare to the S&P 500?
COLL trades at 24.8x P/E versus the S&P 500 median of 21.8x. The 14% premium to the market typically reflects higher expected earnings growth or quality.
How does COLL's valuation compare to Healthcare peers?
Collegium Pharmaceutical, Inc. P/E of 24.8x compares to the Healthcare sector median of 24.6x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is COLL's PEG ratio?
COLL PEG ratio is 1.39, based on a P/E of 24.8x and EPS growth of -7.0%. A PEG between 1 and 2 suggests valuation aligns with growth expectations — typically considered fair.
What is COLL's earnings yield?
COLL earnings yield is 4.03%, the inverse of its 24.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.